DCR-MYC: Phase I started

Dicerna began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV DCR-MYC, with a starting dose of 0.1 mg/kg, given on days 1, 8 and 15 in 28-day cycles in about 66 patients with solid t...